GlaxoSmithKline
United States
3304 articles about GlaxoSmithKline
-
Week in Review: Breakthrough Depression Drug, RSV and GLP-1 Lawsuits, and Earnings Season Shows C...
8/4/2023
A transformational moment in the treatment of depression, GSK takes first shot in a vaccine patent war with Pfizer, a Louisiana woman sues Novo Nordisk and Lilly, and companies face a steep COVID-19 cliff. -
The lawsuit alleges that Pfizer infringed GSK’s patents on respiratory syncytial virus shots. The complaint comes just months after both companies had their respective RSV vaccines approved.
-
The FDA has approved Jemperli as an add-on to chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient or microsatellite instability-high.
-
While GlaxoSmithKline is anticipating a slower uptake of respiratory syncytial virus vaccine Arexvy, CEO Emma Walmsley said Wednesday the company is pinning much of its growth on the vaccine’s performance.
-
The infectious diseases market is expected to reach $150 billion in sales by 2029, with three pharma giants reaping most of its benefits, according to data analytics and consultancy GlobalData.
-
The FDA’s CBER approved nine novel therapies in the first half of 2023, with several more high-profile decisions on deck for the second half of the year.
-
Even at its highest dose, Vir Biotechnology’s investigational flu shot failed to significantly outperform placebo at preventing influenza A illness in a mid-stage study.
-
GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine
7/20/2023
LimmaTech Biologics AG signed an in-license agreement with GlaxoSmithKline Biologicals SA enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK added to its infectious disease pipeline when LimmaTech Bio’s predecessor company, GlycoVaxyn, was acquired by GSK in 2015.
-
The company is handing back a multivalent Shigella vaccine candidate to LimmaTech Biologics, which spun out in 2015 after GSK’s acquisition of GlycoVaxyn for $190 million.
-
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
7/13/2023
GSK plc announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season.
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
6/22/2023
GSK plc announced that the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted in favor of recommending the use of AREXVY in adults aged 60 and older using shared clinical decision making.
-
The FDA has four target action dates this week for three supplemental approvals and one New Drug Approval.
-
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
6/1/2023
GSK plc announced the launch of the COiMMUNITY Initiative to help reduce health inequities and set a new precedent for adult immunization rates in the US, which continue to remain below pre-pandemic levelsi.
-
Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate looms.
-
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/11/2023
SCYNEXIS, Inc. announced financial results for the first quarter ended March 31, 2023.
-
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
5/8/2023
CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.
-
As the COVID-19 market dries up, Moderna looks to FDA approval of its other vaccines including a 2024 commercial launch of its investigational RSV vaccine for older adults.
-
The regulatory decision marks a turning point in the RSV race in what’s expected to be a competitive space.
-
Phase III data for Pfizer's respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.
-
Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, based on late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting.